New! View Conference Abstract Titles, Authors, and Poster Numbers

Abstracts for poster presentations must be submitted via myAACR. Receipt of abstracts will be acknowledged by email to the individual designated as the presenting author. If you do not receive confirmation or have trouble submitting online, please contact programs@aacr.org

The abstract submission deadline has passed. 

It is understood that if a poster abstract is accepted, at least one of the authors will register in advance for the meeting and be in attendance at the poster session. If for any reason an abstract must be withdrawn, please contact programs@aacr.org no later than Tuesday, November 27, 2017, 12:00 pm EST.

Abstract Categories:

  • Emerging Advances in Imaging Technologies
  • Novel Ligands and Target Identification 
  • Imaging Cancer Immunotherapy: Cell-Based Therapies
  • Imaging Cancer Immunotherapy: Checkpoint Blockade, Resistance, and Targeted Therapies
  • Early Detection of Cancer: Liquid Biopsies and Imaging
  • Pathways for Clinical Translation: Novel Agents and Strategies
  • Modeling Cancer: In Silico, In Vitro, In Vivo  
  • Optics in the Oncology Surgical Suite
  • Super-Resolution Imaging of Cancer Biology and Metastasis
  • Imaging Cancer Metabolism
  • Other

General Information 

  1. Abstracts must be submitted via myAACR by Tuesday, October 31, 2017. AACR and SNMMI will not accept abstracts that are not submitted by the deadline.
  2. Incomplete submissions will not be processed.
  3. Please verify your information carefully before submitting. Authors can edit their abstracts until they are officially submitted. After clicking “submit,” you may view, but not edit, this abstract up until the abstract deadline by logging back in to myAACR.
  4. Presenting authors of accepted abstracts will be notified (via email) within 3-4 weeks of the abstract deadline.
  5. Submission of an abstract constitutes a commitment by the author(s) to present if accepted. Failure to present and register for the meeting, if not justified, will jeopardize future acceptance of abstracts.
  6. There is a limit of four (4) abstract submissions per investigator. A maximum of two (2) abstracts per investigator will be accepted. If an abstract is selected, the presenter must be one of the co-authors listed.
  7. Investigators should not submit the same research more than once. Moreover, different investigators should not separately submit the same research. Abstracts that appear to be duplicate versions of a single study will be rejected.
  8. The submitter acts on behalf of all authors and, in submitting the abstract, transfers to SNMMI the copyright and all other rights in the material comprising the abstract if the abstract is accepted. Authors reserve the following: a) all proprietary rights other than copyright, such as patent rights; and b) the right to use all or part of the abstract in future works of their own. SNMMI, as holder of the copyright on the accepted abstract, reserves all right to create derivative works in both print and digital formats.
  9. All abstracts are disclosed to members of the scientific program committee, as well as AACR and SNMMI employees as necessary in connection with the meeting. Abstracts are accepted on the basis of scientific merit determined by our qualified abstract reviewers. Those abstracts that are accepted for poster presentation will be published and titles and authors will be publicly available in advance of the meeting. Abstracts not accepted for presentation are not published and remain confidential. Notwithstanding these policies and procedures, SNMMI is not subject to any confidentiality requirements with respect to submitted abstracts. In addition, compliance with any disclosure or nondisclosure requirements that apply to researchers or research sponsors (whether under federal securities laws, contract agreement, or otherwise) is the sole responsibility of the researcher and/or sponsor.
  10. Accepted abstracts will be published in the final Program and Proceedings available onsite at the meeting and in the online version of the February 2018 edition of The Journal of Nuclear Medicine.